In a significant advancement within perinatal pharmacology and neurodevelopmental research, a comprehensive systematic review and meta-analysis recently published in the Journal of the American Academy of Child & Adolescent Psychiatry has reexamined the association between prenatal acetaminophen exposure and the risk of offspring developing neurodevelopmental disorders (NDDs), including autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). This study, led by Dr. Anick Bérard at the University of Montreal and CHU Sainte-Justine, Montréal, stands as a pivotal contribution that challenges previous claims linking acetaminophen use during pregnancy with increased neurodevelopmental risk, reinforcing confidence in this widely used analgesic’s safety profile for expectant mothers and healthcare providers worldwide.
Acetaminophen, also known as paracetamol outside the United States, represents the most frequently consumed over-the-counter medication among pregnant women, with estimates indicating usage in approximately 70% of all pregnancies globally. It is widely regarded for its efficacy in managing mild to moderate pain and fever without the regulatory and prescription barriers characteristic of many other pharmacological agents. However, concerns have surfaced over the past several years following reports and commentaries suggesting potential neurodevelopmental risks to the fetus when exposed to acetaminophen in utero. These publications, particularly a 2021 commentary, sparked widespread apprehension within both medical communities and the public, magnifying scrutiny on what was once considered routine and benign medication use during gestation.
The current systematic review sought to address these concerns with a rigorously methodological lens, responding directly to critiques of earlier investigations which were characterized by limitations such as selective inclusion criteria, ambiguous exposure metrics, reliance on narrative rather than quantitative synthesis, and inadequate control for confounding variables, including genetic and environmental factors. Dr. Bérard’s team executed an exhaustive search across prominent bibliographic repositories and grey literature sources, identifying sixteen eligible epidemiological studies for inclusion. By applying stringent analytic frameworks typical of high-quality systematic reviews adhering to PRISMA standards, the investigators quantified potential biases and performed sensitivity analyses to elucidate the true nature of the observed associations.
A particular methodological strength of this review was the incorporation of quantitative bias analyses, enabling the appraisal of systematic errors such as measurement inconsistencies of acetaminophen usage during pregnancy and variable definitions of neurodevelopmental outcomes. The inherent difficulty in assessing acetaminophen exposure epidemiologically arises from its ubiquitous over-the-counter availability and irregular, as-needed consumption patterns, which complicate accurate dose quantification and temporal correlation with critical neurodevelopmental windows in utero. These challenges often introduce exposure misclassification and confounding, which can either exaggerate or mask real risks. Therefore, the meta-analytic approach taken here accounts explicitly for such methodological hurdles, enhancing the reliability of the conclusions drawn.
Interestingly, while initial pooled results indicated a modest but statistically significant association between prenatal acetaminophen use and increased ADHD risk, a deeper probing employing sibling-controlled studies—which inherently adjust for shared familial and genetic confounders—revealed that this association was not substantiated. Sibling comparison designs are regarded as a gold standard in observational epidemiology for disentangling environmental effects from inherited predispositions. The absence of a significant risk in these analyses strongly suggests that previously observed correlations may be attributable, at least in part, to residual confounding and not causally implicated in ADHD pathogenesis.
The study’s principal conclusion underscores that the detected slight elevation in ADHD risk linked to prenatal acetaminophen exposure is likely non-causal and manifests from methodological biases and alternative interpretations, such as genetic susceptibilities shared between mothers and offspring, rather than direct pharmacological teratogenicity or neurotoxicity. Consequently, this research advocates that existing recommendations from authoritative bodies—including the Centers for Disease Control and Prevention (CDC), the American College of Obstetricians and Gynecologists (ACOG), and The Society of Obstetricians and Gynecologists of Canada (SOGC)—which endorse acetaminophen as a safe analgesic option during pregnancy, remain justified and should continue to guide clinical practice.
The implications of this study resonate broadly throughout multiple domains, including clinical care, public health policy, and patient education. Pregnant individuals, already navigating a landscape of complex health decisions, confront myriad anxieties about medication safety and fetal well-being; providing evidence-based reassurance that acetaminophen use does not confer increased risk for major neurodevelopmental disorders alleviates a critical area of uncertainty. Moreover, the reaffirmation of acetaminophen’s safety profile ensures pregnant women retain access to a trusted, effective analgesic without undue fear, preventing physical discomfort or untreated conditions that could otherwise adversely impact maternal and fetal health.
Dr. David Coghill from the University of Melbourne, an esteemed expert in developmental mental health who commented on the study, emphasized the critical role of methodological rigor in producing trustworthy scientific findings. He noted that the absence of an association between prenatal acetaminophen use and disorders like autism or ADHD is congruous with the prevailing consensus among global regulatory and professional organizations. Furthermore, Dr. Coghill highlighted that these updated findings challenge recent assertions from U.S. governmental announcements, calling for a recalibration of public messaging to align with the highest quality evidence to prevent unnecessary alarmism.
Beyond clinical reassurance, this review also sets a new methodological benchmark for evaluating pharmacological safety in pregnancy, illustrating how systematic reviews equipped with bias quantification and sibling-controlled analyses can provide nuanced insight into complex exposures with confounding challenges. The approach demonstrated here could serve as a model for future investigations evaluating similar questions around prenatal exposures and long-term neurodevelopmental outcomes, encouraging researchers to prioritize comprehensive, integrative methods over fragmented or simplistic analyses.
While the current findings alleviate prior concerns, the authors prudently recommend continued research efforts aimed at refining exposure assessments, exploring mechanistic pathways, and elucidating subpopulations that might exhibit differential vulnerability. The field would benefit from prospective cohort studies with precise pharmacokinetic documentation and inclusion of genetic and epigenetic profiling to untangle subtle influences that may be obscured in aggregate analyses. Additionally, interdisciplinary collaboration incorporating pharmacology, neurobiology, epidemiology, and clinical specialties promises to deepen understanding of how maternal medication use intersects with fetal neurological development.
In summary, this landmark systematic review and meta-analysis advances scientific understanding by definitively addressing long-standing uncertainties surrounding acetaminophen use during pregnancy and childhood neurodevelopmental risks. The comprehensive evaluation of existing evidence indicates no credible causal link between prenatal acetaminophen exposure and increased risk of ASD or ADHD, rebutting earlier, less methodologically robust claims. These conclusions not only reinforce international clinical guidelines but also embody the importance of rigorous scientific inquiry for informing patient care and public health policy with clarity and confidence.
Subject of Research: People
Article Title: Systematic Review and Meta-Analysis: Acetaminophen Use During Pregnancy and the Risk of Neurodevelopmental Disorders in Childhood
News Publication Date: November 6, 2025
Web References:
References:
This research was funded by the Center for Truth in Science. The funder was not involved in the design, analyses, or interpretation of findings. The study adheres to PRISMA guidelines.
Keywords: acetaminophen, pregnancy, neurodevelopmental disorders, autism, ADHD, systematic review, meta-analysis, epidemiology, pharmacology, prenatal exposure, bias analysis, sibling comparison
